Abstract 1452
Background
Metastasis is the main cause of death in colon cancer patients. RBP-Jκ, which is the main transcription mediator of Notch signaling, is involved in colon cancer development but its function in colon cancer metastasis is still unclear. Here we aimed to find out the function of RBP-Jκ in colon cancer metastasis and its underlying mechanisms of modulating the interaction between colon cancer cells and tumor- associated macrophages (TAMs).
Methods
Cell migration, invasion and epithelial to mesenchymal transition (EMT) were used to reflect cell metastasis ability. A oc-culture system was adopted to research the mutual regulation between colon cancer cells and TAMs. Gain- and loss-of-function experiments and TGF-β/Smad3 pathway activator and inhibitor were used to determine the underlying mechanisms of RBP-Jκ and TAMs in regulating colon cancer metastasis in vitro and in vivo. RNA sequencing was performed to find out the regulating factor between colon cancer cell and TAMs. RBP-Jκ and E-cadherin expression and TAMs infiltration were examined in 201 colon cancer patients by immunohistochemical assay and were analyzed combined with clinical parameters.
Results
RBP-Jκ and TAMs promoted colon cancer cell metastasis through the TGF-β/Smad3 pathway and secreting of TGF-β, respectively. RBP-Jκ in colon cancer cell facilitated TAMs to secret TGF-β through secreting CXCL11. RBP-Jκ and E-cadherin was highly expressed in colon cancer tissues and para-tumor tissues, respectively. And there are more TAMs infiltrated in colon cancer tissues. RBP-Jκ expression and TAMs infiltration were negatively associated with E-cadherin expression and overall survival and positively associated with metastasis. RBP-Jκ and E-cadherin expression and TAMs infiltration were independent prognostic factors in colon cancer patients.
Conclusions
Our research demonstrated that colon cancer cells with high RBP-Jκ expression secreted CXCL11 to enhance TGF-β secretion of TAMs which facilitated colon cancer metastasis. RBP-Jκ exrpression and TAMs infiltration were associated with colon cancer metastasis and acted as prognostic factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenjuan Wang.
Funding
National Natural Science Foundation of China (No. 81502099); Key laboratory of tumor precision medicine open project of Shaanxi province (No. KLTPM-SX2018-B3); The scientific research fund of the first affiliated hospital of Xi’an Jiaotong University (2018MS-06).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5134 - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).
Presenter: OLIVIER COLOMBAN
Session: Poster Display session 2
Resources:
Abstract
4410 - Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
5077 - Response to Pegylated Liposomal Doxorubicin (PLD) and Weekly Paclitaxel (wpac) in Platinum Resistant (PR) Ovarian Cancer (OC) by BRCA mutation status
Presenter: Louise Bremer
Session: Poster Display session 2
Resources:
Abstract
3483 - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Presenter: Bradley Monk
Session: Poster Display session 2
Resources:
Abstract
5423 - OCTAVE - A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Presenter: Iain McNeish
Session: Poster Display session 2
Resources:
Abstract
1385 - Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
Presenter: Natalie Ngoi
Session: Poster Display session 2
Resources:
Abstract
2090 - Phase 1b/2a study assessing the safety and efficacy of adding AL3818 (Anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
Presenter: David Miller
Session: Poster Display session 2
Resources:
Abstract
1960 - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month Follow-up Results of the Dose Escalation Phase
Presenter: Jermaine Coward
Session: Poster Display session 2
Resources:
Abstract
4288 - Hybrid capture-based genomic profiling of circulating tumor DNA (ctDNA) from patients with ovarian cancer
Presenter: Mi Yang
Session: Poster Display session 2
Resources:
Abstract
3433 - Tumor Microvessel Density for predicting Nintedanib activity: data from the randomized CHIVA trial (a GINECO study)
Presenter: Maud Villemin
Session: Poster Display session 2
Resources:
Abstract